Clinical Trial Detail

NCT ID NCT02206763
Title Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gilead Sciences
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + Momelotinib

Age Groups: adult

No variant requirements are available.